| NRG-1, ng/ml |
217 ± 170 |
|
Serum |
n=9 |
[43] |
NRG-1 correlates with exercise capacity |
|
0.77 ± 0.37 |
|
Serum |
n=36 |
[64] |
NRG-1 correlates with proangiogenic factors, VEGF and Angiopoietin-1 |
|
5.3 ± 8.8 |
0.9 [0.6, 7.0] |
Platelet-free plasma |
n=10 |
[63] |
Circulating NRG-1 is functionally inactive |
|
9.0 ± 11.4 |
0.4 |
Plasma |
n=62 |
[176] |
NRG levels are reduced after exposure to cardiotoxic chemotherapy |
|
|
2.6 [0.2, 19.1]/4.1 [2.0, 12.9] |
Serum/plasma |
n=21 |
[70] |
NRG-1 inversely correlates with CAD severity |
|
|
1.4 [0.2, 14.2] |
Serum |
n=319 |
[177] |
No changes during acute coronary syndrome |
|
|
4.4 [2.8, 8.7] |
Serum |
n=899 |
[71] |
Circulating NRG-1 is associated with heart failure severity and risk of death or cardiac transplantation |
| NRG-4, ng/ml |
|
2.3 [1.1, 3.7] |
Serum |
n=129 |
[65] |
The level of circulating NRG-4 is inversely associated with the risk of Type 2 diabetes mellitus |
|
1.1 ± 0.9 |
|
Serum |
n=57 |
[78] |
Circulating NRG-4 is inversely associated with the risk of acute coronary syndrome |
|
|
0.08 [0, 0.55] |
Serum |
n=83 |
[24] |
The circulating NRG-4 is an independent risk factor associated with diabetes |
|
4.1 ± 2.0 |
|
Plasma |
n=41 |
[178] |
Circulating level of NRG-4 is reduced in diabetic peripheral neuropathy |
|
1.4 ± 0.2 |
|
Plasma |
n=32 |
[27] |
NRG-4 inversely correlates with the severity of CAD |
|
1.4 ± 0.1 |
|
Serum |
n=24 |
[179] |
NRG-4 is increased in patients with Type 2 diabetes mellitus |
